Ennature Biopharma Advances Women’s Health Science With Fast-Acting Shatavari and Sustained-Release Ginger

NOIDA, India, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Ennature Biopharma is expanding the clinical evidence for its Aspargize and Gingeren botanical ingredients, addressing two distinct areas of women’s health: menopause and menstrual health. The botanical formulations pair Shatavari for menopausal support with sustained-release ginger for menstrual comfort.

The findings come amid growing interest in evidence-based women’s health solutions and ahead of World Menopause Month and SupplySide Global in October.

Aspargize is a standardized Shatavari (Asparagus racemosus) root extract developed for menopausal support. A recently published multicenter, randomized, double-blind, placebo-controlled trial in Natural Resources for Human Health evaluated 70 peri- and postmenopausal women who received either 400 mg of Aspargize (Shatavari root extract) or a placebo daily for 56 days.

Researchers reported significant improvements in menopausal symptoms, and quality of life, along with the reductions in the frequency and severity of hot flashes, with measurable changes in several areas beginning within two weeks. Additional outcomes included improvements in the mood, sleep quality and stress reduction. The study also evaluated hormonal markers, cortisol, safety, and tolerability.

“As women’s health receives greater attention, the nutraceutical industry also has a responsibility to build stronger science around the botanicals being formulated for these different life stages,” said Pragya Bhartia Barwale, managing director of Ennature Biopharma. “For menopause, women are looking beyond one symptom. The Aspargize research allowed us to examine multiple outcomes, including hot flashes, mood, sleep, stress, and overall quality of life.”

Ennature is also advancing research on Gingeren, a sustained-release ginger ingredient standardized to at least 20% total gingerols and developed for menstrual health and female sexual wellness. Its patented sustained-release technology is designed to deliver total gingerols for more than 10 hours, with the improved tolerability at a 200 mg daily dose. Clinical research in women with primary dysmenorrhea (menstrual pain) found reductions in pain intensity and duration, along with improvements in daily functioning.

“The future of botanical innovation is not necessarily finding the next new plant,” said Barwale. “There is tremendous opportunity in taking botanicals we already understand and using better science and technology to improve how they are standardized, delivered and formulated.”

Aspargize and Gingeren are part of Alkemist Assured, an Alkemist Labs transparency program providing independent third-party testing for botanical identity, potency and purity.

Ennature Biopharma will present the research behind Aspargize and Gingeren at SupplySide Global, Oct. 26-30 in Las Vegas, Booth 4872. The company will also introduce Berbisol, its bio-enhanced berberine ingredient for metabolic health. Discover the full Ennature Biopharma portfolio at: https://ennaturebiopharma.com

About Ennature Biopharma
Ennature Biopharma Limited is an independent natural products company that was established in 2009 as the natural products division of India Glycols Limited (IGL) and became a standalone company following its demerger from IGL, effective Sept. 1, 2026. Ennature Biopharma develops and manufactures high-value, plant-based active ingredients for the pharmaceutical and nutraceutical industries, with a focus on botanical science, quality and sustainable manufacturing.

Building on its origins as IGL’s natural products division and the company’s four decades of renewable, agriculture-based expertise, Ennature Biopharma carries forward a foundation in green technology and sustainable manufacturing. The company sources many of its botanicals through direct relationships with farmers in India and incorporates green solvents, recycling and zero-discharge processes into its manufacturing operations. Ennature Biopharma maintains international quality and manufacturing certifications, supports customers with regulatory documentation for global markets, and supplies ingredients to partners and customers in more than 30 countries. https://ennaturebiopharma.com

Photos accompanying this announcement are available at 
https://www.globenewswire.com/NewsRoom/AttachmentNg/53d0c544-5348-492d-a4e6-2e372756b73f
https://www.globenewswire.com/NewsRoom/AttachmentNg/5c62622b-c404-415f-b170-a7ba9f2c1bc2
https://www.globenewswire.com/NewsRoom/AttachmentNg/df08392b-c0bf-465c-8543-e20d550fd80f
https://www.globenewswire.com/NewsRoom/AttachmentNg/9bfb8420-f595-4a4a-9948-a649957f182b

Media Contact:
Amy Summers
212-757-3419 | amy@pitchpublicitynyc.com
Pitch Publicity®

Ennature Biopharma Women's Health

Ennature Biopharma is expanding the clinical evidence for its Aspargize and Gingeren botanical ingredients, addressing two distinct areas of women’s health: menopause and menstrual health.

Aspargize Study Results

Researchers reported significant improvements in menopausal symptoms with Aspargize, including quality of life, along with the reductions in the frequency and severity of hot flashes, with measurable changes in several areas beginning within two weeks.

Pragya Bhartia Barwale, Managing Director, Ennature Biopharma

Pragya Bhartia Barwale, managing director of Ennature Biopharma, says women are looking beyond one symptom when it comes to menopause.

Gingeren Clinical Research

Clinical research in women with primary dysmenorrhea (menstrual pain) found reductions in pain intensity and duration, along with improvements in daily functioning when taking Gingeren.